Archive for: Regulatory

Diagonal Bio AB resolves on a directed issue of units to all external underwriters

, , ,
The Board of Directors of Diagonal Bio AB ("Diagonal Bio" or the "Company") has today, based on the authorisation granted by the Extraordinary General Meeting on 17 January 2025 resolved on a directed issue of 2,587,768 units to underwriters…

Diagonal Bio AB’s rights issue of units oversubscribed

, , , ,
The subscription period in Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights Issue was subscribed to a total of…

Stall Goop conducts pilot test of LAMPlify®

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has signed an agreement with Stall Goop regarding a pilot test of LAMPlify®.  The three-month pilot test, starting in February 2025, aims to enhance equine health and performance…

Diagonal Bio announces positive pilot test results and secures order from StallZet

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of the successful completion of…

The subscription period of Diagonal Bio AB’s rights issue of units commences today

, , ,
Today, 23 January 2025, the subscription period in Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6 million, with preferential rights for the Company’s existing shareholders,…

Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units

, , ,
The subscription period of Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on a directed issue of units, commences…

Bulletin from the Extraordinary General Meeting of Diagonal Bio AB on 17 January 2025

, , ,
Today, January 17, 2025, an Extraordinary General Meeting was held in Diagonal Bio AB. A summary of the adopted resolutions follows below. Resolution on reduction of the share capital for allocation to non-restricted equity The general…

Diagonal Bio expands its testing panel for horses with EHV-5 detection

, , , ,
Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces the expansion of its equine diagnostic testing panel to include the detection of Equine Herpesvirus type 5 (EHV-5), following the recommendation of Daniel Redén –…

Kallelse till extra bolagsstämma i Diagonal Bio AB

, , ,
Aktieägarna i Diagonal Bio AB, org.nr 559248-8984, kallas härmed till extra bolagsstämma fredagen den 17 januari 2025 kl. 13.00 på Medicon Village, i huvudbyggnaden The Spark, Scheeletorget 1, Lund.Rätt att delta och…

The Board of Directors of Diagonal Bio AB resolves on a directed issue of units and a rights issue of units to focus on validation of LAMPlify®’s commercial interest

, , , ,
Board of Directors of Diagonal Bio AB (”Diagonal Bio” or the ”Company”) has today resolved on a directed issue of units consisting of shares and consideration free warrants of series TO 2, of initially approximately SEK…